UPLOAD Filing
BIO-PATH HOLDINGS, INC.
Date: April 18, 2025 · CIK: 0001133818 · Accession: 0000000000-25-004150
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12601
Letter
Re: Bio-Path Holdings, Inc. Offering Statement on Form 1-A Filed April 11, 2025 File No. 024-12601 Dear Peter Nielsen:
April 18, 2025
Peter Nielsen Chief Executive Officer Bio-Path Holdings, Inc. 4710 Bellaire Boulevard, Suite 210 Bellaire, TX 77401
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: William R. Rohrlich, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 18, 2025 Peter Nielsen Chief Executive Officer Bio-Path Holdings, Inc. 4710 Bellaire Boulevard, Suite 210 Bellaire, TX 77401 Re: Bio-Path Holdings, Inc. Offering Statement on Form 1-A Filed April 11, 2025 File No. 024-12601 Dear Peter Nielsen: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William R. Rohrlich, Esq. </TEXT> </DOCUMENT>